MINDMAZE THERAPEUTICS HOLDING SA Net Assets
MINDMAZE THERAPEUTICS HOLDING SA net assets. Based on the latest financial reports, MINDMAZE THERAPEUTICS HOLDING SA (MMTX) has net assets worth CHF35.93 Million CHF (≈ $45.43 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF44.11 Million ≈ $55.76 Million USD) and total liabilities (CHF8.18 Million ≈ $10.34 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore MINDMAZE THERAPEUTICS HOLDING SA (MMTX) equity growth momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CHF35.93 Million |
| % of Total Assets | 81.46% |
| Annual Growth Rate | 44669.22% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Net Assets of MINDMAZE THERAPEUTICS HOLDING SA (2024–2025)
Net assets of MINDMAZE THERAPEUTICS HOLDING SA from 2024 to 2025. This chart illustrates how MINDMAZE THERAPEUTICS HOLDING SA's net assets have evolved over time, based on quarterly financial data. See how leveraged is MINDMAZE THERAPEUTICS HOLDING SA's balance sheet to measure how much of total assets are equity-financed.
Annual Net Assets for MINDMAZE THERAPEUTICS HOLDING SA (2024–2025)
The table below shows the annual net assets of MINDMAZE THERAPEUTICS HOLDING SA from 2024 to 2025. For live market cap and overall valuation, see market cap of MINDMAZE THERAPEUTICS HOLDING SA.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CHF38.34 Million ≈ $48.47 Million |
+44482.56% |
| 2024-12-31 | CHF86.00K ≈ $108.73K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to MINDMAZE THERAPEUTICS HOLDING SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1065900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
MINDMAZE THERAPEUTICS HOLDING SA Net Assets Breakdown (December 2025)
MINDMAZE THERAPEUTICS HOLDING SA net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CHF49.01 Million | 127.84% |
| Total Equity | CHF38.34 Million | 100.00% |
MINDMAZE THERAPEUTICS HOLDING SA Competitors by Market Cap
The table below lists competitors of MINDMAZE THERAPEUTICS HOLDING SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Yeou Yih Steel Co Ltd
TWO:9962
|
$28.57 Million |
|
Cleo Diagnostics Ltd
AU:COV
|
$28.57 Million |
|
Birman Wood and Hardware Ltd
TA:BIRM
|
$28.57 Million |
|
Sangshin Electronics Co. Ltd
KQ:263810
|
$28.59 Million |
|
Wulff-Yhtiot Oy
HE:WUF1V
|
$28.54 Million |
|
Stakeholder Gold Corp
V:SRC
|
$28.51 Million |
|
Airtime Partecipazioni SpA
PA:ALMEX
|
$28.51 Million |
|
Morixe Hermanos SACI
BA:MORI
|
$28.51 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MINDMAZE THERAPEUTICS HOLDING SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 86,000 to 38,341,000, a change of 38,255,000 (44482.6%).
- Net loss of 9,906,000 reduced equity.
- Other factors increased equity by 48,161,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CHF-9.91 Million | -25.84% |
| Other Changes | CHF48.16 Million | +125.61% |
| Total Change | CHF- | 44482.56% |
Book Value vs Market Value Analysis
This analysis compares MINDMAZE THERAPEUTICS HOLDING SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.54x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2025-12-31 | CHF0.25 | CHF0.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MINDMAZE THERAPEUTICS HOLDING SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -25.84%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1542.99%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.34x
- Recent ROE (-25.84%) is below the historical average (-13.50%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2024 | -1.16% | 0.00% | 0.00x | 1.08x | CHF-9.60K |
| 2025 | -25.84% | -1542.99% | 0.01x | 1.34x | CHF-13.74 Million |
Industry Comparison
This section compares MINDMAZE THERAPEUTICS HOLDING SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $317,304,877
- Average return on equity (ROE) among peers: -25.90%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MINDMAZE THERAPEUTICS HOLDING SA (MMTX) | CHF35.93 Million | -1.16% | 0.23x | $28.56 Million |
| Addex Therapeutics Ltd (ADXN) | $16.29 Million | -165.85% | 0.33x | $3.89 Million |
| Bachem Holding AG (BANB) | $384.21 Million | 12.14% | 0.60x | $5.42 Billion |
| BB Biotech AG (BION) | $2.78 Billion | 20.81% | 0.00x | $2.90 Billion |
| Bioversys AG (BIOV) | $59.81 Million | -36.50% | 0.52x | $159.24 Million |
| Basilea Pharmaceutica AG (BSLN) | $127.94 Million | 31.42% | 1.20x | $686.09 Million |
| Idorsia Ltd (IDIA) | $-660.96 Million | 0.00% | 0.00x | $1.03 Billion |
| Molecular Partners AG (MOLN) | $107.29 Million | -59.45% | 0.61x | $125.91 Million |
| Newron Pharmaceuticals SpA (NWRN) | $21.09 Million | -33.66% | 0.50x | $235.69 Million |
| Relief Therapeutics Holding AG (RLF) | $21.28 Million | -2.05% | 0.67x | $36.33 Million |
About MINDMAZE THERAPEUTICS HOLDING SA
MindMaze Therapeutics Holding SA operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally. The company offers MindPod system, a supervised in-clinic neurorehabilitation system designed to initiate and intensify the recovery journey; MindMotion GO, which extends protocolized neurotherapeutics into outp… Read more